Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease  

作　　者：Kay Cheong Teo Shu-Leong Ho 

机构地区：[1]Division of Neurology,Department of Medicine,University of Hong Kong,Hong Kong,China [2]Research Centre of Heart,Brain,Hormone and Healthy Aging(HBHA),University of Hong Kong,Hong Kong,China

出　　处：《Translational Neurodegeneration》2013年第1期124-133,共10页转化神经变性病（英文）

基　　金：The authors’work is supported by the Henry G Leong Endowed Professorship;the Donation Fund for Neurology Research,University of Hong Kong.

摘　　要：There is a substantial amount of evidence from experimental parkinsonian models to show the neuroprotective effects of monoamine oxidase-B(MAOB)inhibitors.They have been studied for their potential disease-modifying effects in Parkinson’s disease(PD)for over 20 years in various clinical trials.This review provides a summary of the clinical trials and discusses the implications of their results in the context of disease-modification in PD.Earlier clinical trials on selegiline were confounded by symptomatic effects of this drug.Later clinical trials on rasagiline using delayed-start design provide newer insights in disease-modification in PD but success in achieving the aims of this strategy remain elusive due to obstacles,some of which may be insurmountable.

关 键 词：Parkinson's disease Monoamine oxidase-B inhibitors Disease-modification Neuroprotection SELEGILINE RASAGILINE 

分 类 号：R74[医药卫生—神经病学与精神病学]